News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,359 Results
Type
Article (14104)
Company Profile (282)
Press Release (249973)
Section
Business (79505)
Career Advice (152)
Deals (13233)
Drug Delivery (36)
Drug Development (50422)
Employer Resources (31)
FDA (5709)
Job Trends (5128)
News (144404)
Policy (10040)
Tag
Academia (905)
Alliances (21624)
Alzheimer's disease (790)
Antibody-drug conjugate (ADC) (74)
Approvals (5705)
Artificial intelligence (94)
Bankruptcy (101)
Best Places to Work (4566)
Biotechnology (232)
Breast cancer (126)
Cancer (1083)
Cardiovascular disease (88)
Career advice (132)
CAR-T (89)
Cell therapy (261)
Clinical research (40538)
Collaboration (423)
Compensation (175)
COVID-19 (1023)
C-suite (112)
Cystic fibrosis (74)
Data (1117)
Diabetes (103)
Diagnostics (1265)
Earnings (29150)
Events (47623)
Executive appointments (342)
FDA (6189)
Funding (397)
Gene editing (75)
Gene therapy (193)
GLP-1 (337)
Government (1073)
Healthcare (6582)
Infectious disease (1073)
Inflammatory bowel disease (100)
IPO (7245)
Job creations (860)
Job search strategy (127)
Layoffs (195)
Legal (1384)
Lung cancer (161)
Manufacturing (100)
Medical device (2575)
Medtech (2576)
Mergers & acquisitions (6215)
Metabolic disorders (308)
Neuroscience (1095)
NextGen: Class of 2025 (2014)
Non-profit (853)
Northern California (1296)
Obesity (165)
Opinion (96)
Parkinson's disease (88)
Patents (78)
People (25349)
Phase I (14297)
Phase II (18861)
Phase III (11925)
Pipeline (491)
Postmarket research (853)
Preclinical (5990)
Radiopharmaceuticals (210)
Rare diseases (239)
Real estate (1415)
Regulatory (8424)
Research institute (933)
Series A (79)
Southern California (1158)
Startups (1969)
United States (10269)
Vaccines (188)
Weight loss (95)
Date
Today (67)
Last 7 days (347)
Last 30 days (1419)
Last 365 days (20455)
2025 (2205)
2024 (20586)
2023 (22431)
2022 (26842)
2021 (27833)
2020 (23378)
2019 (16256)
2018 (11769)
2017 (13771)
2016 (11853)
2015 (14367)
2014 (10406)
2013 (7500)
2012 (7541)
2011 (7629)
2010 (7432)
Location
Africa (148)
Asia (17087)
Australia (2897)
California (2958)
Canada (940)
China (263)
Colorado (113)
Connecticut (127)
Delaware (69)
Europe (36819)
Florida (338)
Georgia (88)
Illinois (190)
Indiana (71)
Maryland (384)
Massachusetts (2340)
Minnesota (118)
New Jersey (733)
New York (815)
North Carolina (463)
Northern California (1296)
Ohio (97)
Pennsylvania (562)
South America (208)
Southern California (1158)
Texas (326)
Washington State (286)
264,359 Results for "ait therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced that results of its EfficAPSI real-world study evaluating the impact of Stallergenes Greer liquid sublingual AIT on asthma onset and evolution in patients with allergic rhinitis have been published in the Lancet Regional Health-Europe.
May 2, 2024
·
9 min read
Drug Development
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A)1 in patients with C9ORF72 amyotrophic lateral sclerosis (ALS)2.
April 5, 2023
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.
November 20, 2023
·
6 min read
Biotech Beach
Calibre Scientific Expands European Presence and Chromatography Offering With AIT France Acquisition
Calibre Scientific is pleased to announce the acquisition of AIT France, a manufacturer and distributor of innovative consumables for analytical chemistry and chromatography.
January 25, 2021
·
1 min read
Press Releases
Allogene Therapeutics Announces Participation in February Investor Conferences
February 4, 2025
·
2 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Press Releases
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
·
6 min read
Press Releases
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 4, 2025
·
4 min read
Press Releases
Neumora Therapeutics Announces Leadership Transition
February 13, 2025
·
5 min read
1 of 26,436
Next
